Your SlideShare is downloading. ×
0
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Esclerodermia: mitos, verdades y retos
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Esclerodermia: mitos, verdades y retos

869

Published on

Por: Dr. Marco Matucci Cerinic (ITA) …

Por: Dr. Marco Matucci Cerinic (ITA)
XIII Congreso Colombiano de Reumatologia 2011 Barranquilla

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
869
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
25
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. ColombianCongressofRheumatology, Barranquilla 2011<br />Systemic Sclerosis,myths,  truths &amp; challenges<br />Marco MatucciCerinic<br />Dept Biomedicine, DivRheumatology<br />UnivFlorence, Italy<br />
  • 2. SSc- myths,  truths &amp; challenges<br /><ul><li>Myth-SScisasfibroticdisease…
  • 3. Truth-SScis a dreadfuldisease…
  • 4. Challenge- SSc can bediagnosedveryearly…
  • 5. Conclusions</li></li></ul><li>Myth-SScisasfibroticdisease…<br />“…wasteduntiloneisliterally a mummy,…”<br /> William Osler 1898 <br />
  • 6. Myth-SScisasfibroticdisease…<br />SScis more thanthat,<br />Itis a vasculardisease… !!??<br />
  • 7. Barbara G. May 2005<br />Paolieri<br />Lidia T. January 2005<br />G.P, March 2004<br />
  • 8. disease evolution <br />lung, heart, GI, kidney<br />intermediate<br />skin<br />thickness<br />early<br />late<br />DIFFUSE SSc<br />Dermal inflammation<br />Early dSSc<br />Established disease<br />pulmonary hypert., malabsorption<br />intermediate<br />late<br />early<br />LIMITED SSc<br /> 2 5 10 20<br />disease duration (years)<br />Medsger T &amp; Steen V, SystemicSclerosis, 1995, p 51,Williams &amp; Wilkins<br />
  • 9. What’s going on under the skin… into the vessels ?<br />Endothelial damage and apoptosis<br />Progressive arteriolar alteration with intima hypertrophy and progressive stranglement of the vessel lumen<br />Skin, Lung, Kidney, Heart<br />
  • 10. Fleischmajeret al, J amAcadDermatol 1980<br />
  • 11. Tha<br />TAT<br />VIIa<br />IL-2<br />F 1+2<br />TF<br />IIa<br />IL-1<br />DS<br />Fb<br />t-PA<br />Lp<br />vW<br />VCAM<br />TNF<br />CF<br />PAI<br />G<br />vW<br />F<br />ICAM<br />PA<br />E-sel<br />GF<br />uPAr<br />of Endothelial Cells<br />Apoptosis <br />Collagen<br />Smooth<br />Muscle Cells<br />Fibroblasts<br />MatucciCerinicet al SeminarsArthritisRheum 2003<br />
  • 12. Vasculopathy of SSc complications…“the challenge for the future”<br />Intimal proliferation<br />Adventitial fibrosis<br />Lumen narrowing &amp; obliteration<br />Fingers<br />Lung<br />Kidney<br />Heart<br />PAH<br />Ulcers/gangrene<br />SRC<br />Infarct<br />
  • 13. Hypoxia,Thrombosis<br /> ROS<br />Continuous Vasospasm<br /> ENDOTHELIAL DAMAGE<br /> RAYNAUD’s Phenomenon<br />TELEANGECTASIAS<br />ULCERS<br />
  • 14. normal<br />early<br />active<br />late<br />
  • 15. <ul><li> Calcium Channel blockers
  • 16. Iloprost </li></ul>January 2006<br />
  • 17. August 2006<br /><ul><li> Nifedipine
  • 18. Iloprost weekly infusions
  • 19. Patient coming seldom for medication</li></li></ul><li>
  • 20. Patient is painful again, the 5° right finger is again problematic <br />
  • 21.
  • 22. Digitalarterywith a thrombusformation due toendothelialcelldysfunction: increasedplateletactivity and increasedthrombogenicity in SSc<br /> HE x 15, CourtesyofPetrosEfthimiou, MD, NY<br />
  • 23. 11.3.03<br />23.12.02<br />28.4.03<br />
  • 24. Truth…SScis a dreadfuldisease…<br />William Osler (1849-1919)<br /> “Sclerodermais a shrinkingskinof steel”<br /> In its more aggravatedformsof diffuse sclerodermaisoneof the mostterribleofallhumanills. LikeTithonustowitherslowly and likehimtobebeaten down and marred, wasteduntiloneisliterally a mummy, encased in anevershrinking, slowlycontractingskinof steel, is a fate notpictured in anytragedy, ancient or modern.<br />J Cutan &amp; Genitourinar Dis 1898, 16, 49<br />
  • 25. Self-portrait<br />Embrace<br />General Chef du Barbare<br />
  • 26. 1940<br />Captive <br />
  • 27. Death and Fire, 1940<br />
  • 28.
  • 29. Independent riskfactorsforincreasedmortality(Cox-proportional hazard model)<br />FVC&lt;80%<br />Proteinuria<br />HR= <br />3.34<br />HR= <br />1.64<br />Pulmonary hypertension<br />Dyspnoea<br />(PAPsys &gt;40 mmHg)<br />HR=<br />2.02<br />HR= <br />1.61<br />Huegleet al ARD 2010<br />
  • 30. Survival Curves of Scleroderma Patients With Pulmonary Hypertension, Lung Involvement, or No Major Organ Involvement<br />100<br />90<br />80<br />None<br />70<br />60<br />Survival, %<br />50<br />Lung Involvement (without PHTN)<br />40<br />30<br />PHTN<br />20<br />10<br />0<br />0<br />1<br />2<br />3<br />4<br />5<br />6<br />7<br />8<br />9<br />10<br />11<br />12<br />13<br />Years From Diagnosis of PHT<br />Koh et al. BrJ Rheumatol. 1996;35:989-993.<br />
  • 31. Scleroderma renal crisisClinical picture<br />Grade IV retinopathy<br /><ul><li>Rapidly progressive renal impairment
  • 32. New-onset accelerated phase hypertension
  • 33. Headaches
  • 34. Visual disturbances
  • 35. Encephalopathy with seizures
  • 36. Flash pulmonary oedema
  • 37. Fevers / malaise
  • 38. Pericardial effusion
  • 39. +/- MAHA
  • 40. Hypereninaemia
  • 41. ARF + occlusive renal vascular lesions may occur without hypertension at presentation (Helfrich 1989)</li></ul>Schistocytes - MAHA<br />Courtesy of Dr C Denton, RFH, UK<br />
  • 42. Scleroderma renal crisis - biopsy features<br />thrombotic vascular occlusion<br />hypertensive vascular damage<br />glomerularischaemia<br />fibrosis<br />Courtesy of Dr C Denton, RFH, UK<br />
  • 43. Challenge<br />SSc can bediagnosedveryearly<br />
  • 44. VeryEarlySystemicSclerosis<br />Raynaud’s phenomenon<br />Pre-SSc<br />Puffy Fingers<br />UCTD<br />MCTD<br />Anti-nuclear antibodies<br />Capillaroscopy<br />MatucciCerinicet al , AnnRheumDis2009<br />
  • 45. Raynaud Fenomenus,Quo Vadis… ?<br />
  • 46. Patients suspect for very early SSc, characterised by <br />Raynaud’s phenomenon,<br />puffy fingers/sclerodactily<br />antinuclear antibodies<br />1st level<br />Red Flags<br />Suspicion<br />Evaluation of patients <br />Capillaroscopy &amp; SSc-specific antibodies<br />2nd level<br />If either one is positive, diagnosis of very early SSc &amp; further<br /> investigations<br />If negative…<br />diagnosis<br /><ul><li> differential diagnosis
  • 47. send patient to to other specialist </li></ul>HRCT , PFT &amp; Esophageal manometry <br />If positive…<br />If negative…<br />Choice of treament <br />Follow up<br />Avouacet al ARD 2010<br />
  • 48. Disease evolution<br />lung, heart, GI, kidney<br />intermediate<br />skin<br />thickness<br />early<br />late<br />DIFFUSE SSc<br />pulmonary hypert., malabsorption<br />intermediate<br />late<br />LIMITED SSc<br />early<br /> 2 5 10 20<br />disease duration (years)<br />Medsger T &amp; Steen V, SystemicSclerosis, 1995, p 51,Williams &amp; Wilkins<br />
  • 49. May we treat a very early SSc?<br />A Windowofopportunity<br />
  • 50. disease evolution <br />lung, heart, GI, kidney<br />intermediate<br />skin<br />thickness<br />early<br />late<br />DIFFUSE SSc<br />Dermal inflammation<br />Early dSSc<br />Established disease<br />pulmonary hypert., malabsorption<br />intermediate<br />late<br />early<br />LIMITED SSc<br /> 2 5 10 20<br />disease duration (years)<br />Medsger T &amp; Steen V, SystemicSclerosis, 1995, p 51,Williams &amp; Wilkins<br />
  • 51. Facts…<br />When observing a Raynaud’s ph an accurate diagnostic procedure should be used to differentiate between a primary or a secondary form<br /> Follow up of these patients is mandatory <br />Raynaud’s ph is the first sign of a very early Systemic Sclerosis<br /> “red flags” must always induce the suspect of a very early SSc !<br />
  • 52. The facts<br />The Mythoffibrosisistoo late !!<br />WestillhaveTruths &amp; Challenges…<br />
  • 53. What are the followingcases ? An earlySSc or somethingveryearly ?Where do we position thesepatients in the diseaseevolution ?<br />
  • 54.
  • 55.
  • 56.
  • 57. Cardiac MRI<br />Patient dies 10 months after the diagnosis<br />
  • 58. DE 15.4.04Finger edema &amp; RaynaudNVC- Active patternAnticentromereposLES Dysfunction<br />
  • 59. <ul><li>RP &amp; puffyfingers
  • 60. Topo I
  • 61. NVC late
  • 62. FVC &amp; DLCO normal
  • 63. chest HRCT normal</li></li></ul><li>RP<br />ANA/Topo I pos<br />NVC active<br />Simona C. December 2004<br />Are these already SSc ?<br />Early or very early ?<br />RP<br />ANA/ACA pos<br />NVC early<br />Claudia P. 2005<br />
  • 64. DE 2010RPANA/ACA posNVC activeLES dysfunctionFVC &amp; DLCO normal<br />
  • 65. RP<br />ANA/Topo I pos<br />NVC active<br />Diffuse SSc- Six months<br />Simona C. December 2004<br />RP<br />ANA/ACA pos<br />NVC early<br />Limited SSc-Three years<br />Claudia P. 2005<br />
  • 66. Do we really have to treat these patients… ?<br />WE DO NOT KNOW AS EVIDENCE BASE DATA ARE NOT AVAILABLE…<br />&amp; predictors of evolution are missing but STILL REMAINS MANDATORY to block the disease evolution and organ damage<br />An early aggressive therapymightbechosenwhen:: <br /> Topo I antibodies/RNA pol III<br />rapidlyprogressingskininvolvement<br />Tendonfrictionrubs<br />
  • 67. The window of opportunity…!!!<br />Paul Klee<br />The window<br />
  • 68. Educationisofparamountimportance !!<br />
  • 69. www.eustar.org<br />www.W-S-F.org<br />Scleroderma<br />Foundation<br />
  • 70. VEDOSS Very Early Diagnosis Of SSc<br /><br /> Partnership between EULAR, EUSTAR and FESCA toestablisha programme to:<br />Create clinics devoted to the early diagnosis of SSc<br />Educate primary care professionals throughout Europe <br />In the earliest symptoms of SSc<br />(Raynaud’s, ANA  capillaroscopy / anti-nuclear antibody tests)<br />To send any patient presenting with Red Flags to special SSc clinics <br />Launch datetocoincidewithEuropean Scleroderma Awareness Day: 29th June 2010<br />
  • 71. DeptRheumatology AVC<br />Dept Biomedicine &amp; DivRheumatology AOUC<br />Dept Medicine &amp; DENOtheCentre<br />UniversityofFlorence<br />Dr. ML Conforti<br />Dr A Righi<br />Dr G Baccano<br />Dr. S MaddaliBongi<br />Dr. A Del Rosso<br />Dr. D Melchiorre<br />Dr. M Maresca<br />Dr. F Bandinelli<br />Dr. S BellandoRandone<br />Dr. S Guiducci<br />Dr. G Salvadorini<br />Dr. F Porta<br />Dr. J Blagojevic<br />Dr. G Carnesecchi<br /> Dr F Galluccio<br />Dr S Cappelli<br />Dr V Denaro<br />Dr T Barskova<br />Dr R De Luca<br />Dr L Giovannini<br />Dr A Calabrò<br />Dr E Bellucci<br />Dr M Orlandi <br />Clinical Trial Unit<br />Dr. F Nacci<br />Dr. F Bartoli<br /> Dr F Peruzzi<br /> Dr C Bruni <br />DigitalUlcersUnit<br />Dr. G Fiori<br /> Signora F Braschi<br />RegionalReferenceCentreforSystemicSclerosis<br />Dottssa P Cerboni<br />LaboratoryUnit<br />Dr M Manetti<br />Dr C Ceccarelli<br />Dr E Romano<br />Young Adults Clinic<br />Prof F Falcini<br />

×